Walleye Capital
FHTX icon

Walleye Capital’s Foghorn Therapeutics FHTX Stock Holding History

Walleye Capital’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$165K Sell
34,445
-46,903
-58% -$257K ﹤0.01% 3446
2025
Q4 		$439K Buy
81,348
+47,040
+137% +$213K ﹤0.01% 3033
2025
Q3 		$168K Hold
34,308
– – ﹤0.01% 3426
2025
Q2 		$161K Buy
34,308
+1,469
+4% +$6.14K ﹤0.01% 3518
2025
Q1 		$120K Sell
32,839
-1,209
-4% -$5.51K ﹤0.01% 3542
2024
Q4 		$161K Sell
34,048
-10,879
-24% -$79.3K ﹤0.01% 3890
2024
Q3 		$418K Buy
44,927
+27,782
+162% +$201K ﹤0.01% 3465
2024
Q2 		$98.6K Buy
+17,145
New +$102K ﹤0.01% 4725

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Walleye Capital's FHTX Position: Q1 2026 in Review

Walleye Capital reduced its Foghorn Therapeutics (FHTX) stake by 58% in Q1 2026, selling an estimated $257K and leaving 34,445 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #3446.

Walleye Capital first reported a position in FHTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $439K in Q4 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Walleye Capital held 34,445 shares of Foghorn Therapeutics worth $165K as of Q1 2026.
  • Walleye Capital sold 46,903 Foghorn Therapeutics shares in Q1 2026, an estimated $257K.
  • Foghorn Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3446 holding.
  • Walleye Capital first reported a position in Foghorn Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Walleye Capital's Foghorn Therapeutics position peaked at $439K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.